A Technology Sale Is Not a Clean Exit: Innovation Authority, Yissum, and Deal Friction
The board is explicitly talking about a merger or a sale of activity and technology, but that path runs through Innovation Authority restrictions, a Yissum license, and layers of shared rights. The real question in any future transaction is not only who will pay, but what can actually be transferred, in which structure, and how much of the consideration leaks out on the way.
The Deal Does Not Start With Price, But With Rights
The main article focused on whether cost cuts bought SavorEat time. This continuation isolates the other path the company itself has now put on the table: a merger, a sale of activity, or a strategic transaction around the technology. In the annual report, one of the company’s stated 2026 objectives is to exploit a business opportunity that would enable a merger or a sale of the company’s activity and technology, including an investment and/or strategic transaction in the technology. In the immediate report dated March 26, 2026, the board went one step further and instructed management to focus resources on opportunities for a merger and/or a sale of activity or technology, alongside financing alternatives.
That is the real issue. Once a company shifts from trying to commercialize on its own to actively pursuing a strategic outcome, the value of the IP is supposed to turn from a theoretical asset into something that can be transferred for cash. At SavorEat, that package is not sitting cleanly inside the company. It is wrapped in three layers: the Israel Innovation Authority, the commercialization license from Yissum, and rights that may be jointly held by the company and Yissum. So a future transaction will not stand or fall only on the quality of the technology. It will depend on the structure of the transfer, the approvals required, and the royalty streams attached to it.
What matters most is that the report draws a sharp line between commercializing a product and transferring know-how. A product developed on supported know-how can be marketed and sold abroad without the same approval. That does not mean the know-how, the manufacturing rights, or the licensing layer can be moved just as easily. Once the board starts talking about a sale, that distinction stops being a legal footnote and becomes the economics of the deal.
Innovation Authority: You Can Export the Product, But You Cannot Freely Move the Know-How
The report states that technology developed with Innovation Authority support is subject to restrictions on manufacturing, knowledge transfer, and rights connected to that knowledge. The key point is that the company itself says Innovation Authority approval is not required for exporting, marketing, and selling products developed on supported know-how, but approval is required for transferring the know-how, sharing it with others, pledging it, or placing it in escrow.
That distinction matters. A reader focused only on SavorEat’s US commercialization path could assume that completing the US regulatory process automatically brings a technology-sale option closer. The report says otherwise. Selling a product abroad is not the same legal event as moving the knowledge abroad. If a strategic buyer wants the technology itself, the manufacturing rights, or the know-how layer outside Israel, that becomes a different path, with prior written approval from the Innovation Authority and with a very different potential payment burden.
The report says that transferring manufacturing abroad or granting manufacturing rights outside Israel may trigger increased royalties of up to 3 times the support amount plus interest. Transferring know-how outside Israel may require, in addition to prior approval, a payment of up to 6 times the funding received plus interest, and in any event not less than the funding received, net of royalties already paid. That is not just a legal clause. It is a mechanism that can reshape the deal economics.
The friction is not limited to a foreign buyer. Even transferring supported know-how to another Israeli entity requires Innovation Authority approval and an undertaking by the recipient to remain subject to the law, the use restrictions, and the royalty obligation. At the same time, the report shows that the company is already subject to ongoing royalties on revenue at a 3% to 4% rate, subject to the law and related procedures, and the royalty table explicitly lists the Innovation Authority as a revenue-based royalty recipient.
The implication is straightforward: if the board tries to turn the technology into cash through a transaction, this is not only about finding a counterparty. The company needs a structure that can live with a regulator’s approval process, an existing royalty layer, and the possibility of additional payments if the transaction is deemed a know-how transfer or a relocation of manufacturing. The report is also blunt about the downside. Non-compliance can lead to economic sanctions, the loss of commercialization and other economic rights, a demand to repay the full support plus interest, linkage, and penalties, and in the case of unapproved know-how transfer abroad, even criminal exposure.
Yissum: SavorEat Has an Exclusive Worldwide License, Not Full Ownership
The second friction point sits in the commercialization agreement with Yissum. SavorEat holds an exclusive worldwide license to commercially use the patents, patent applications, and know-how developed at the Hebrew University, but the report says explicitly that full ownership of the technology remains with Yissum. That matters because in a strategic transaction the question is not only whether the company has exclusive access, but whether it can actually sell clean title.
The economic wrapper around that license is also far from marginal. The company owes Yissum royalties of 3% of net sales, with reductions possible in some cases but never below 1.5%, and 15% of the consideration received from sublicensing. So if the strategic path is built as a sublicensing structure rather than a share sale, part of the economics leaks out at the Yissum layer before Innovation Authority issues even begin.
The report also says sublicenses can be granted only with Yissum’s approval and under the terms of the agreement. So a structure built around a strategic partner, an exclusive operator, or an international commercialization partner is not just a commercial question. It also runs through Yissum’s consent and a pre-defined sharing of economics.
Even the geographic scope is not completely frictionless. Under the license terms, the company bears the costs of registration, protection, and maintenance of patents in the US, China, England, Germany, France, Italy, and Spain, and decisions on additional countries are taken jointly. If the company decides it is not desirable to register, protect, or maintain a patent in a specific country, the license is carved out of that country. So even in a transaction that sounds global, the real territorial package still has to be mapped.
| Layer | What the report says | Why it creates deal friction |
|---|---|---|
| Innovation Authority | Know-how transfer, pledges, and escrow require prior approval; manufacturing abroad may trigger up to 3x the support amount; know-how abroad may trigger up to 6x | Headline consideration can erode, and closing depends on an external approval path |
| Yissum | Yissum retains full ownership of the technology; SavorEat operates under an exclusive license | A buyer may be getting a contractual rights package, not clean IP title |
| Sublicensing | 15% of sublicensing consideration goes to Yissum, subject to Yissum approval | A licensing-led structure may leak economics from day one |
The Shared-Patent Layer Makes the Package Less Clean
The most delicate part of the report is the treatment of newly generated development output. The company is supposed to own the results of activities it directs, or that third parties perform under its direction, but if a university employee, including the researchers, is considered an inventor of such a patent, then the company and Yissum become joint owners and the patent is registered in both names. The report adds that ownership and rights in research results and joint patents are subject to Innovation Authority rules.
That is exactly what makes the “we can just sell the technology and move on” narrative too simplistic. Part of the value may sit in the license, part in output owned by the company, and part in joint patents that are subject to both Yissum and the Innovation Authority. The more a transaction depends on moving the IP itself, rather than simply transferring shares, the more central that mapping becomes.
There is also a downside clause that matters in diligence. According to the note, the company granted Yissum an irrevocable assignment of its rights in joint patents if the company enters bankruptcy or liquidation, or if it fails to bear the registration, protection, or maintenance costs of a joint patent. That does not mean this scenario is around the corner. It does mean that recovery value in the IP does not sit entirely inside the company under every scenario. For a buyer, lender, or strategic partner, that is a material diligence point.
The Real Question Is Deal Structure
The report does not say whether the board is aiming for a share sale, a sale of activity, a technology sale, a strategic license, or a merger into another business. But the documents do establish one rule: the more a transaction relies on know-how transfer, sublicensing, or moving manufacturing outside Israel, the heavier the friction layer becomes. By contrast, the ability to sell products abroad or to commercialize outside Israel does not, by itself, prove that the technology can be transferred on the same basis.
That is why the market can get this wrong in both directions. It is easy to read the board’s language and assume a strategic move offers a fast solution. It is also easy to read the licensing and regulatory restrictions and conclude that any transaction is unrealistic. Both readings go too far. The report does not say such a transaction is impossible. It does say this would not be a clean IP exit, and that structure will determine how much value ultimately remains for shareholders and how much is captured by the regulator, the licensor, and other rights holders.
What Has To Be Clarified Now
- Whether the board is actually examining a share transaction, a sale of activity, a strategic license, or a sublicensing path.
- Which parts of the technology are fully owned by the company, which parts are only licensed from Yissum, and which parts sit in joint patents.
- What Innovation Authority path would be required if the structure includes know-how transfer, manufacturing migration, an IP pledge, or escrow.
- Whether the economics of a possible transaction are being evaluated net of Yissum royalties, Innovation Authority royalties, and any transfer-related payments, not just on a gross headline basis.
Conclusion
SavorEat is not offering only a technology story here. It is offering a technology story with embedded transfer friction. That does not make a transaction impossible, but it does change how any future headline about a merger, sale of activity, or strategic transaction should be read. The obstacle is not only finding a counterparty. It is defining what can be transferred, through which path, and at what net value.
Thesis now: SavorEat’s strategic value will not be determined only by whether someone wants the technology, but by whether an exclusive license, state-supported know-how, and joint patents can be turned into a deal whose value does not leak away on the path to closing.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.